PDP-11

Petauri™ Elects William Fleming and James Robinson to Its Board of Directors

Retrieved on: 
Wednesday, December 6, 2023

NASHVILLE, Tenn., Dec. 6, 2023 /PRNewswire/ -- Petauri Health, a purpose-built pharmaceutical services platform, announced today that two highly regarded healthcare executives, William Fleming and James Robinson, have been elected as members of the company's Board of Directors.

Key Points: 
  • NASHVILLE, Tenn., Dec. 6, 2023 /PRNewswire/ -- Petauri Health , a purpose-built pharmaceutical services platform, announced today that two highly regarded healthcare executives, William Fleming and James Robinson, have been elected as members of the company's Board of Directors.
  • With a nearly 30-year track record at Humana, Dr Fleming is passionate about simplifying healthcare, providing value to consumers, and fostering high-performing teams.
  • Currently the company's Chief Corporate Affairs Officer, William develops and strengthens relationships with government partners to impact public health policy.
  • During his tenure at Humana, William has led various divisions, focusing on clinical integration and improving health outcomes.

Fault Detection and Classification (FDC) Market worth $7.4 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, September 20, 2023

Therefore, fault detection is not only about adhering to industry standards but also about upholding brand reputation and customer trust.

Key Points: 
  • Therefore, fault detection is not only about adhering to industry standards but also about upholding brand reputation and customer trust.
  • North America is expected to hold the second largest share of the fault detection and classification market during the forecast period.
  • North America held the second largest share of ~32% in the fault detection and classification industry in 2022.
  • The growth in this region is attributed to the presence of fault detection and classification system manufacturers as Cognex Corporation, Teledyne Technologies, KLA Corporation, Microsoft, etc.

Fault Detection and Classification (FDC) Market worth $7.4 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, September 20, 2023

Therefore, fault detection is not only about adhering to industry standards but also about upholding brand reputation and customer trust.

Key Points: 
  • Therefore, fault detection is not only about adhering to industry standards but also about upholding brand reputation and customer trust.
  • North America is expected to hold the second largest share of the fault detection and classification market during the forecast period.
  • North America held the second largest share of ~32% in the fault detection and classification industry in 2022.
  • The growth in this region is attributed to the presence of fault detection and classification system manufacturers as Cognex Corporation, Teledyne Technologies, KLA Corporation, Microsoft, etc.

Nosto announces full end-to-end integration with Shopify Markets, giving commerce brands complete control and flexibility over multi-market personalization

Retrieved on: 
Thursday, September 14, 2023

NEW YORK, Sept. 14, 2023 /PRNewswire-PRWeb/ -- Nosto, the leading Commerce Experience Platform (CXP), has announced its integration with Shopify's cross-border management tool, Shopify Markets. Shopify Markets functions as a centralized hub with all the tools needed for merchants to manage global commerce. Merchants can use Shopify Markets to identify, set-up, launch, and optimize international markets—all from their single Shopify store.

Key Points: 
  • Shopify Markets functions as a centralized hub with all the tools needed for merchants to manage global commerce.
  • "The integration with Shopify Markets, and being the first personalization vendor to fully integrate end-to-end, shows our commitment to Shopify merchants looking to grow internationally without sacrificing control over their personalization and commerce experience initiatives in local regions."
  • Full control of multi-market personalization is now a reality for brands leveraging the power of Nosto's CXP and Shopify Markets.
  • For more information on Nosto's CXP and Shopify Markets, visit: www.nosto.com/nosto-shopify-markets
    For more information on Shopify Markets, visit: www.shopify.com/markets

Monetate Announces Company Expansion and 49% QoQ Sales Growth

Retrieved on: 
Wednesday, April 26, 2023

On the heels of its sale to Centre Lane Partners in October 2022 the company completed its first full quarter with a 49% increase in sales, expansion of its executive leadership team, and released new features for Monetate Social Proof .

Key Points: 
  • On the heels of its sale to Centre Lane Partners in October 2022 the company completed its first full quarter with a 49% increase in sales, expansion of its executive leadership team, and released new features for Monetate Social Proof .
  • “Taking the helm as CEO in October, my vision for Monetate is to double down and invest in both our team and our platform.
  • The world's best companies rely on us to deliver an optimal experience to every customer at every interaction,” stated Brian Wilson, CEO of Monetate.
  • The company expects to continue on a growth trajectory in 2023 as the need for personalization continues to accelerate.

Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Monday, March 13, 2023

To support this strategy, Ovid instituted cost-cutting measures that began in 2022 and continue into this year.

Key Points: 
  • To support this strategy, Ovid instituted cost-cutting measures that began in 2022 and continue into this year.
  • In addition, Ovid is eligible to receive non-dilutive capital from Takeda, if and when soticlestat is successfully approved and marketed.
  • Business development strategy: Ovid intends to conduct disciplined business development activities with a focus on clinical stage assets and enabling technologies to complement its portfolio of anti-seizure medicines.
  • The annual decrease was a result of the above mentioned cost cutting and personnel reduction efforts undertaken in 2022.

Saint Jean Carbon Receives Conditional Approval For Acquisition of Solid Ultrabattery

Retrieved on: 
Thursday, April 8, 2021

The Company has provided the supporting documentation required by the TSX-V with respect to the Acquisition.

Key Points: 
  • The Company has provided the supporting documentation required by the TSX-V with respect to the Acquisition.
  • Final approval of the Acquisition remains subject to TSX-Vs review of the documentation.
  • The Company will provide a further update on the Acquisition once the TSX-V has completed its review of the documentation.
  • Such statements include statements with respect to: (i) completion of the Acquisition; and (ii) the approval by the TSX-V of the Acquisition.

Stromasys: Government IT paralysis can be instantly cured with "lifting and shifting" legacy applications

Retrieved on: 
Tuesday, April 14, 2020

40-year old Cobol-based systems need extra capacity and the expertise of engineers who have the know-how to address decades-old servers.

Key Points: 
  • 40-year old Cobol-based systems need extra capacity and the expertise of engineers who have the know-how to address decades-old servers.
  • The Charon solutions, by Stromasys, is "lift and shift" software; can be installed remotely and does not require re-authentication or re-certification by users.
  • Within a few days, legacy applications can be migrated on to modern hardware with legacy server emulation and can quickly scale, enabling antiquated systems to run on modern platforms or the cloud.
  • Stromasys is a pioneer in enterprise-class cross-platform legacy server emulation solutions, providing modern infrastructure for legacy applications running on SPARC, Digital VAX and Alpha; HP; and PDP-11 servers.

Mumps - Pipeline Review, H1 2019 Featuring Cadila Healthcare, GlaxoSmithKline and Sinovac Biotech - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 16, 2019

The Mumps (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Mumps and features dormant and discontinued projects.

Key Points: 
  • The Mumps (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Mumps and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Mumps (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • Formulate corrective measures for pipeline projects by understanding Mumps (Infectious Disease) pipeline depth and focus of Indication therapeutics.